Cancer Research Annual Meeting 2010  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 1270, February 1, 2007. doi: 10.1158/0008-5472.CAN-06-2184
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jazirehi, A. R.
Right arrow Articles by Bonavida, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jazirehi, A. R.
Right arrow Articles by Bonavida, B.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy

Ali R. Jazirehi, Mario I. Vega and Benjamin Bonavida

Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California

Requests for reprints: Benjamin Bonavida, Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles School of Medicine, A2-060A CHS, 10833 Le Conte Avenue, Los Angeles, CA 90024-1747. Phone: 310-825-2233; Fax: 310-206-3865; E-mail: bbonavida{at}mednet.ucla.edu.

Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has significantly improved the treatment outcome of lymphoma patients. Via an elusive mechanism, a subpopulation of patients becomes unresponsive and/or relapses. To recapitulate various aspects of acquired resistance, rituximab-resistant (RR) clones were established from lymphoma lines and compared with parental cells. Surface CD20 expression was diminished in the clones. The clones neither responded to rituximab-mediated growth reduction or complement-dependent cytotoxicity nor underwent apoptosis in response to cross-linked rituximab. Rituximab failed to chemosensitize the RR clones, which exhibited constitutive hyperactivation of the nuclear factor-{kappa}B and extracellular signal-regulated kinase 1/2 pathways, leading to overexpression of B-cell lymphoma protein 2 (Bcl-2), Bcl-2–related gene (long alternatively spliced variant of Bcl-x gene), and myeloid cell differentiation 1 and higher drug resistance. Unlike parental cells, rituximab neither inhibited the activity of these pathways nor diminished the expression of resistant factors. Pharmacologic inhibitors of the survival pathways or Bcl-2 family members reduced the activity of these pathways, diminished antiapoptotic protein expression, and chemosensitized the RR clones. These novel in vitro results denote that continuous long-term rituximab exposure culminates in RR clones that do not respond to rituximab-mediated effects, have altered cellular signaling dynamics, and exhibit different genetic and phenotypic properties compared with parental cells. The data also reveal that although RR clones exhibit higher resistance to rituximab and cytotoxic drugs, these clones can be chemosensitized following treatment with pharmacologic inhibitors (e.g., dehydroxymethylepoxyquinomicin, bortezomib, PD098059) that target survival/antiapoptotic pathways. The findings also identify intracellular targets for potential molecular therapeutic intervention to increase treatment efficacy. The significance and potential clinical relevance of the findings are discussed. [Cancer Res 2007;67(3):1270–81]




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Baritaki, K. Yeung, M. Palladino, J. Berenson, and B. Bonavida
Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Cancer Res., November 1, 2009; 69(21): 8376 - 8385.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. A. Thomas, S. O'Brien, J. L. Jorgensen, J. Cortes, S. Faderl, G. Garcia-Manero, S. Verstovsek, C. Koller, S. Pierce, Y. Huh, et al.
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Blood, June 18, 2009; 113(25): 6330 - 6337.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H.-P. Gerber, M. Kung-Sutherland, I. Stone, C. Morris-Tilden, J. Miyamoto, R. McCormick, S. C. Alley, N. Okeley, B. Hayes, F. J. Hernandez-Ilizaliturri, et al.
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
Blood, April 30, 2009; 113(18): 4352 - 4361.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Terui, Y. Mishima, N. Sugimura, K. Kojima, T. Sakurai, Y. Mishima, R. Kuniyoshi, A. Taniyama, M. Yokoyama, S. Sakajiri, et al.
Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
Clin. Cancer Res., April 1, 2009; 15(7): 2523 - 2530.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Dalle, S. Dupire, S. Brunet-Manquat, L. Reslan, A. Plesa, and C. Dumontet
In vivo Model of Follicular Lymphoma Resistant to Rituximab
Clin. Cancer Res., February 1, 2009; 15(3): 851 - 857.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Z. Meng, N. Mitsutake, M. Nakashima, D. Starenki, M. Matsuse, S. Takakura, H. Namba, V. Saenko, K. Umezawa, A. Ohtsuru, et al.
Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor-{kappa}B Inhibitor, Enhances Antitumor Activity of Taxanes in Anaplastic Thyroid Cancer Cells
Endocrinology, November 1, 2008; 149(11): 5357 - 5365.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Stolz, G. Hess, P. S. Hahnel, F. Grabellus, S. Hoffarth, K. W. Schmid, and M. Schuler
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
Blood, October 15, 2008; 112(8): 3312 - 3321.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
X. Zhou, W. Hu, and X. Qin
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Oncologist, September 1, 2008; 13(9): 954 - 966.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Ann. Onc., March 1, 2008; 19(3): 560 - 565.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. H. Olejniczak, F. J. Hernandez-Ilizaliturri, J. L. Clements, and M. S. Czuczman
Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression
Clin. Cancer Res., March 1, 2008; 14(5): 1550 - 1560.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Clin. Cancer Res., March 1, 2008; 14(5): 1561 - 1570.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Powles, J. Stebbing, S. Montoto, M. Nelson, B. Gazzard, C. Orkin, A. Webb, and M. Bower
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease
Blood, December 1, 2007; 110(12): 4132 - 4133.
[Full Text] [PDF]


Home page
ASH Education BookHome page
C. Bello and E. M. Sotomayor
Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond
Hematology, January 1, 2007; 2007(1): 233 - 242.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.